Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Beijing Continent Pharmaceutical Co., Ltd. China

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Website:
www.bjcontinent.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Qin Li
Associate Director,Business Development 

Beijing medical award foundation China

Our foundation provides services for the promotion of medical results,prospective project research,medical project cooperation and the cultivation of outstanding talents.
Website:
www.yxjl.org
Partnering Objectives
Headquartner in China
Yes
玲玲 孟
医学部主任 

Betta Pharmaceutical China

China innovative drug R&D company
Website:
www.bettapharma.com
Partnering Objectives
Headquartner in China
Yes
Zhi Jiang
BD manager 

BGI Group China

Founded in 1999, BGI is one of the world's leading life science and genomics organizations.
Website:
www.genomics.cn
Partnering Objectives
Headquartner in China
Yes
Jizhe Sun
Supervisor of the Board of Director’s Office 

bioBAY China

industrial park
Website:
www.biobay.com.cn
Partnering Objectives
Headquartner in China
Yes
lingling gao
investment manager 

BioChange Israel

BioChange is a biotech startup in tissue engineering and regenerative medicine. Our main product is a gelatin based injectable scaffold.

BioChange has developed CellFoam™ , a unique injectable cell adhesive-scaffold that stimulates guided tissue regeneration and supports cell seeding. When CellFoam is injected as stand alone, it completely degrades within the body after about 3 months of a remodeling phase, as new functional tissue is formed, replacing the aged or impaired tissue.

Our first human product is a therapy for skin ageing (BlueStim™ product), it modulates fibroblasts' behavior to regenerate new collagen, regaining skin thickness and quality. In other words, it turns aged skin to young.

The core technology can fit various applications in healthcare such as COPD, macular degeneration, neural repair, periodontal disease, and tissue bioprinting.
Website:
http://www.biochange.life/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Finding investors, technology partners and clients
Headquartner in China
No
Medtech Category
Mr. Ishay Attar
CEO 
Functionality
Management

Bioindustry Park Silvano Fumero Italy

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and health care centers.
Website:
https://www.bioindustrypark.eu/
Company Size (Fulltime employees)
11-50
Year of foundation
1998
Partnering Objectives
Please specify your partnering goal
Meet companies and investors in order to start new partnerships and activities (scouting and due diligences for investors, EU projects, international cooperation, licensing-out and promotion of our startups)
Headquartner in China
No
Biotech/Pharma Category
Dr. Arianna Floris
Life sciences Innovation Manager 
Functionality
Business Development

Biomissile Biotech China

A startup biotech focusing on novel therapeutic antibody discovery and development, particularly in fully human nanobody and bispecifics. Recently closed a Series A fund raising (USD $25M ).

苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。
Website:
https://mp.weixin.qq.com/s/YekLgSGB6l66OISNrw6j8g
Company Size (Fulltime employees)
Nov-50
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Licensing-in China rights
Headquartner in China
Yes
Biotech/Pharma Category
Chao Tu
President & CEO 
Functionality
Management

Bionus Biotech Finland

Bionus Biotechnology was established in 2018， with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.

The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main United Statesges is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.
Website:
1
Partnering Objectives
Headquartner in China
No
Xuexin Li
CEO 

BioPegasus, LLC United States

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Website:
not available
Company Size (Fulltime employees)
1-10
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
1) Seeking investment(s) for developing cost-effective and minimally invasive blood antibody biomarker tests for Alzheimer’s disease diagnosis and early detection (a 3-year project); and/or 2) Looking for any interested party(ies) to work together.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
biomarker and target discovery technology platform|||
Biotech/Pharma Asset Stage
Your Research Tool and Service name
A unique and transformative λ phage cDNA expression library construction and screening (not phage display). A cost-effective and robust novel biomarker and target discovery technology platform for novel diagnostic and therapeutic development.
Service Description
BioPegasus' technology platform provides a revolutionary tool for systematically and thoroughly studying novel molecular interactions and mechanism of actions with any molecule of interest and allowing unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time in novel diagnostic and therapeutic development.
Target client type
1) As diagnostic and early detection tests for Alzheimer's disease: general population for early detection (POCT, age 50 years and better) and patients for severity and diagnosis (lab tests); 2) As a research tool: client types include research institutions and diagnostic IVD, biotech and pharma companies
Slides Deck
(pdf, 957.61KB)
Dr. Tianlin Ma
Founder 
Functionality
Management